Crinetics Pharmaceuticals is a clinical stage pharmaceutical company that develops medical treatments for rare endocrine-related tumors and diseases. The company's lead product candidate is Paltusotine, an oral medication that has completed phase III clinical trials for acromegaly and phase II clinical trials to treat other related tumors. Crinetics is also developing two other drugs in phase I clinical trials for the treatment of congenital hyperinsulinism, Cushing's, and congenital adrenal hyperplasia diseases.